Market Overview
The UK biotechnology market was valued at USD 22.00 Billion in 2024 and is projected to reach USD 41.47 Billion by 2033, growing at a CAGR of 7.22% during the forecast period 2025-2033. The industry growth is driven by increasing chronic disease incidence, advancements in genomics, gene-editing technologies like CRISPR, and expanding applications in agriculture. Government support and R&D incentives further fuel innovation and market expansion.
Study Assumption Years
Base Year: 2024
Historical Year/Period: 2019-2024
Forecast Year/Period: 2025-2033
UK Biotechnology Market Key Takeaways
The UK biotechnology market size was USD 22.00 Billion in 2024 with a forecast CAGR of 7.22% between 2025 and 2033.
Growing incidence of chronic diseases drives demand for new treatments and biotechnological innovations.
Strong government support, including funding through UKRI and Innovate UK, boosts early-stage ventures and R&D activities.
The NHS Genomic Medicine Service processed over 810,000 genomic tests in 2024, an 8% increase from the previous year.
Increasing applications in sustainable agriculture, such as genetically modified crops and bio-based fertilizers, enhance growth.
Fast-paced advancements in gene and cell therapies position the UK as a global leader in precision medicine.
Sample Request Link: https://www.imarcgroup.com/uk-biotechnology-market/requestsample
Market Growth Factors
The UK biotechnology market is significantly driven by the rising prevalence of chronic and genetic diseases. This surge increases demand for innovative treatments and personalized medicine solutions. Enhancements in genome sequencing, bioinformatics, and data analytics facilitate the development of therapies tailored to individual genetic profiles. The NHS Genomic Medicine Service highlights this trend by processing over 810,000 genomic tests in 2024, marking an 8% increase from the prior year. Such data underscores expanding clinical adoption of genomic technologies, alongside initiatives like the 100,000 Genomes Project strengthening precision healthcare.
Robust government support fuels market growth through substantial public funding from bodies like UK Research and Innovation (UKRI) and Innovate UK. Innovate UK operates with a £1.1 billion annual budget, supporting over 450,000 innovators and generating £3.61 in private-sector investment for every £1 spent. Initiatives such as the Life Sciences Vision 2030 and R&D tax incentives stimulate investments in biopharma and medical technology. Additionally, the ecosystem benefits from science parks and university-industry collaborations that help translate scientific research into market-ready therapies, reinforcing the UK’s leadership in genomics, personalized medicine, and synthetic biology.
Sustainable agriculture solutions also drive market expansion. The farming sector faces resource shortages, climate stress, and increasing food demand, requiring innovative biotech techniques. Biotechnological developments include genetically modified crops resistant to pests, diseases, and climatic extremes, reducing pesticide and fertilizer use and environmental pollution. Public opinion favors gene editing, with 69% of British adults supportive of it for food security. Advances in bioinformatics and genomics enable crops with optimized nutrient content and growth traits, alongside bio-based fertilizers and biopesticides that lessen environmental harm and improve soil quality.
Market Segmentation
By Product Type:
Instruments
Reagents: Accounting for 45.8% market share, reagents are essential for various applications like drug discovery, diagnostics, genomics, and research, driving significant demand.
Software and Services
By Technology:
Nanobiotechnology
Tissue Engineering and Regeneration
DNA Sequencing: The largest segment with 36.8% share, vital for genomics, personalized medicine, and molecular diagnostics, supported by projects like the 100,000 Genomes Project.
Cell-Based Assays
Fermentation
PCR Technology
Chromatography
Others
By Application:
Healthcare: Dominates with 49.6% share, driven by chronic and genetic disease prevalence, aging population, and demand for advanced therapeutics including biopharmaceuticals.
Food and Agriculture
Natural Resources and Environment
Industrial Processing
Bioinformatics
Others
Regional Insights
London leads the UK biotechnology market due to world-class universities, healthcare infrastructure, and numerous biotech startups and incubators. It benefits from strong government funding, private investment, and access to skilled talent fostering innovation in genomics, diagnostics, and personalized medicine. The South East region, proximate to London, hosts science parks and R&D centers supporting pharmaceutical and biotech collaborations, while the North West focuses on bioprocessing and pharmaceuticals with NHS partnerships. These hubs, along with the East of England, Scotland, and other regions, contribute significantly to UK biotechnology innovation.
Recent Developments & News
March 2025: Celex Oncology unveiled a novel treatment targeting sodium overload in tumor cells to control metastatic cancer, involving VGSC inhibitors and monoclonal antibodies.
February 2025: Biocon Ltd launched Liraglutide for diabetes and obesity management after MHRA approval, planning expansion into Europe and the US.
February 2025: Sortera Bio commercialized Deep Screening, an AI-powered platform accelerating biological discovery, supported by AstraZeneca.
February 2025: Tropic prepared to launch non-browning and extended shelf-life bananas using CRISPR, securing regulatory approvals and USD 80 Million in funding.
January 2025: Verdiva Bio secured a USD 411 Million Series A financing for obesity and cardiometabolic therapies, the largest in UK/EU.
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request Sample Customization:- https://www.imarcgroup.com/request?type=report&id=24913&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302